VitD联合美沙拉秦治疗轻中度溃疡性结肠炎的临床疗效研究

Study on clinical efficacy of vitamin D combined with mesalazine on mild-to-moderate ulcerative colitis

目的探讨VitD联合美沙拉秦对轻中度UC的临床疗效,并探讨其作用机制。方法使用计算机产生的简单随机算法将80例患轻中度UC的病人分为研究组和对照组(研究组:40例;对照组:40例),研究组给予美沙拉秦和VitD治疗,对照组给予美沙拉秦和安慰剂治疗,8周后观察两组炎症因子水平、Mayo评分、治疗疗效及其不良反应。结果研究组男18例,女22例,平均年龄(41.30±11.16)岁,平均病程(4.05±1.96)年,对照组男20例,女20例,平均年龄(40.98±10.94)岁,平均病程(3.98±1.98)年,治疗8周后,研究组临床缓解率85%,显著高于对照组60%,差别有统计学意义(P<0.05);研究组临床有效率92.5%、内镜缓解率47.5%显著高于对照组临床有效率77.5%、内镜缓解率25%,统计学上有差异(P<0.05);研究组Mayo评分(1.41±1.08)分显著低于对照组(2.00±1.24)分,统计学上有差异(P<0.05);治疗后研究组的血清炎症因子CRP、TNF-α、IL-6的水平显著低于对照组,差别有统计学意义(P<0.05);两组治疗后的不良反应率差别无统计学意义(P>0.05)。结论VitD联合美沙拉秦比单独使用美沙拉秦能有效提高临床缓解率,促进肠道黏膜愈合,减少炎症反应。

Objective To investigate the efficacy of vitamin D combined with mesalazine in patients with mild-to-moderate ulcerative colitis.Methods Totally 80 patients with mild to moderate ulcerative colitis were enrolled and randomly divided into two groups with a simple random algorithm generated by computer(study group:40 cases;control group:40 cases).The study group was treated with mesalazine and vitamin D,and the control group was treated with mesalazine and placebo.After 8 weeks,two groups of inflammatory factor levels,Mayo score,therapeutic efficacy and adverse reaction were observed.Results The study group had 18 males and 22 females,with an average age(41.30±11.16)and an average course of UC(4.05±1.96)years.The control group had 20 males and 20 females,with an average age(40.98±10.94)years and an average course of UC(3.98±1.98)years.After 8 weeks of treatment,the clinical remission rate of the study group was 85%,significantly higher than the control group was 60%,with the difference was statistically significant(P<0.05).The clinical effective rate of 92.5%and endoscopic remission rate of 47.5%in the study group were significantly higher than the clinical effective rate of 77.5%,endoscopic remission rate of 25%in control group,and the difference was statistically significant(P<0.05).The Mayo score in the study group(1.41±1.08)was significantly lower than the control group(2.00±1.24),and the difference was statistically significant(P<0.05).Serum inflammatory factors CRP,TNF-α,IL-6 in the study group were significantly lower than those in the control group,with differences statistically significant(P<0.05),and there was no statistically difference in adverse reactions between the two groups(P>0.05).Conclusion vitamin D combined with mesalazine can effectively improve the clinical remission rate and promote intestinal mucosal healing compared with mesalazine alone.